Drug Uses

Gris-PEG is prescribed for the treatment of the following ringworm infections: Athlete's foot, Barber's itch (inflammation of the facial hair follicles), Ringworm of the body, Ringworm of the groin and thigh, Ringworm of the nails, Ringworm of the scalp. Because Gris-PEG is effective only for certain types of fungal infections, before treatment your doctor may perform tests to identify the source of infection.

How Taken

Accurate diagnosis of the infecting organism is essential. Adults: Daily administration of 330 mg (as a single dose or in divided amounts) will give a satisfactory response. Children: Approximately 3.3 mg per pound of body weight per day is an effective dose for most children.

Warnings/Precautions

Because Gris-PEG can make you sensitive to light, avoid exposure to intense natural or artificial sunlight. Notify your doctor if you develop lupus erythematosus (a form of rheumatism) or a lupus-like condition. Signs and symptoms of lupus include arthritis, red butterfly rash over the nose and cheeks, tiredness, weakness, sensitivity to sunlight, and skin eruptions. If you are being treated with Gris-PEG for an extended period of time, your doctor should perform regular tests, including periodic monitoring of kidney function, liver function, and blood cell production. Gris-PEG has not been proved safe and effective for the prevention of fungal infections. Gris-PEG may decrease the effectiveness of birth-control pills. Use additional protection while you are taking Gris-PEG. Men should wait at least 6 months after finishing therapy with Gris-PEG before they father a child. Women should avoid becoming pregnant while they are taking the drug.

Missed Dose

Take the missed dose as soon as you remember. If it is almost time for your next dose, skip the one you missed and go back to your regular schedule. Do not take 2 doses at once.

Possible Side Effects

When adverse reactions occur, they are most commonly of the hypersensitivity type such as skin rashes, urticaria, erythema multiform-like drug reactions, and rarely, angioneurotic edema, and may necessitate withdrawal of therapy and appropriate countermeasures. Paresthesias of the hands and feet have been reported rarely after extended therapy. Other side effects reported occasionally are oral thrush, nausea, vomiting, epigastria distress, diarrhea, headache, fatigue, dizziness, insomnia, mental confusion, and impairment of performance of routine activities. Administration of the drug should be discontinued if granulocytopenia occur. When rare, serious reactions occur with Gris-PEG, they are usually associated with high dosages, long periods of therapy, or both.

Storage

Store Gris-PEG tablets at controlled room temperature 15°-30°C (59°-86°F) in tight, light-resistant containers.

Overdose

Any medication taken in excess can have dangerous consequences. If you suspect an overdose of Gris-PEG, seek emergency medical treatment immediately.

More Information

Gris-PEG may intensify the effects of alcohol. If you drink alcohol while taking this medication, your heart may start beating faster and your skin may be flushed. If Gris-PEG is taken with certain other drugs, the effects could be increased, decreased, or altered. It is especially important to check with your doctor before combining Gris-PEG with the following: Blood-thinning drugs such as Coumadin, Barbiturates such as Phenobarbital, Oral Contraceptives.

Disclaimer

This drug information is for your information purposes only, it is not intended that this information covers all uses, directions, drug interactions, precautions, or adverse effects of your medication. This is only general information, and should not be relied on for any purpose. It should not be construed as containing specific instructions for any particular patient. We disclaim all responsibility for the accuracy and reliability of this information, and/or any consequences arising from the use of this information, including damage or adverse consequences to persons or property, however such damages or consequences arise. No warranty, either expressed or implied, is made in regards to this information.

Other info about Gris-peg at Wikipedia.org and other resources:

Prevalence of poor biological response to clopidogrel. A systematic review.
Authors: Mallouk N, Labruyere C, Reny JL, Chapelle C, Piot M, Fontana P, Gris JC, Delavenne X, Mismetti P, Laporte S Abstract The existence of poor biological response to clopidogrel has been shown in some patients. Despite the increasing number of studies, this phenomenon remains difficult to quantify. We performed a systematic review to estimate the prevalence of poor biological response to clopidogrel and investigate the factors known to modulate this. An exhaustive search was performed. Altogether 171 publications were identified, providing data for a total of 45,664 subjects. The estimated prevalence of poor biological response to clopidogrel ranged from 15.9% to 49.5% according to the platelet function assay employed. The assays most frequently used were light transmittance a...

Anti-CD11d monoclonal antibody treatment for rat spinal cord compression injury.
Authors: Weaver LC, Dekaban GA, Brown A Abstract This paper by Hurtado et al. examined responses of spinal cord-injured rats to treatment with a monoclonal antibody to the CD11d integrin, as a replication study of the paper by Gris et al. published in J. Neuroscience, 2004. The Hurtado et al. study addressed a portion of our investigation and obtained similar findings in the experiments that closely replicated ours in methodology and design, specifically the open field locomotor study. The high variability in their study of mechanical allodynia probably precluded detection of effects of the anti-CD11d treatment on this form of neuropathic pain. The lesion assessments were greatly different from those done in the Gris et al. study, and may not have been ideal for the extent of injur...

A common polymorphism in NR1H2 (LXRbeta) is associated with preeclampsia
Conclusions: This study provides the first evidence of an association between the NR1H2 gene and preeclampsia, adding to our understanding of the links between cholesterol metabolism and this disease. (Source: BMC Medical Genetics - Latest articles)

Femtosecond laser–assisted enhancements after laser in situ keratomileusis
We describe a technique of femtosecond laser-assisted enhancement after primary LASIK with a mechanical microkeratome-created flap. The vertical side-cut incision by the femtosecond laser creates a wound configuration that decreases mechanical trauma to the epithelium and prevents epithelial cell migration. These factors may decrease the risk for post-LASIK enhancement epithelial ingrowth.Financial Disclosure: No author has a financial or proprietary interest in any material or method mentioned. Additional disclosures are found in the footnotes. (Source: Journal of Cataract and Refractive Surgery)

Costs of interventions for AIDS orphans and vulnerable childrenRevue systématique: Coûts des interventions pour les orphelins du SIDA et les enfants vulnérablesRevisión sistemática: Costes de Intervenciones para el SIDA en huérfanos y niños vulnerables
Conclusion  More research is needed to improve planning and delivery of interventions for OVC. The paucity of cost and cost‐effectiveness data reflects the limited number of effectiveness studies. Nevertheless, this systematic literature review shows evidence that suggests that in the area of housing, foster care appears to be more cost effective than institutional care (orphanages).Objectif:  Passer en revue la littérature publiée et grise sur les informations concernant l’efficacité, les coûts et la rentabilité des interventions visant à améliorer le bien‐être des orphelins et enfants vulnérables (OEV) à cause du VIH/SIDA dans les pays à faibles et moyens revenus.Méthode:  Nous avons effectué une recherche de littérature publiée dans PubMed et EconLit pour la pé...